

Case Report

Ovarian Solid Pseudopapillary Tumor Resembling Benign Hemorrhagic Cyst on Rapid Frozen Section

Michelle T. Nguyen ¹, Michael Carter,² Zimin Zhao,³ Alireza Abidi,⁴ and Melissa Hodeib⁴

¹Department of Obstetrics and Gynecology, Adventist Health White Memorial, Los Angeles, CA, USA

²Department of Obstetrics and Gynecology, Kaiser Permanente Southern California, Riverside, CA 92505, USA

³Department of Pathology, Kaiser Permanente Southern California, Riverside, CA 92505, USA

⁴Department of Gynecologic Oncology, Kaiser Permanente Southern California, Riverside, CA 92505, USA

Correspondence should be addressed to Michelle T. Nguyen; nguyenmt02@ah.org

Received 13 November 2019; Revised 10 May 2020; Accepted 22 May 2020; Published 1 June 2020

Academic Editor: Cem Ficicioglu

Copyright © 2020 Michelle T. Nguyen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Solid pseudopapillary tumors are rare, with the majority of described cases originating in the pancreas. To date, there are only 10 documented reports of primary ovarian solid pseudopapillary tumors. Here, we describe the case of a 24-year-old woman who presented with worsening pelvic pain and dysmenorrhea. Workup demonstrated a right ovarian solid mass on ultrasound and an elevated serum LDH, which raised concerns for dysgerminoma due to her relatively young age. Therefore, she was taken to the operating room and underwent laparoscopic right salpingo-oophorectomy. On initial rapid frozen section, her ovarian cyst had a grossly hemorrhagic appearance with multiple hemosiderin deposits noted microscopically, which suggested a benign hemorrhagic cyst. However, the final pathology was reported as solid pseudopapillary tumor based on several defining histologic characteristics. Most importantly, immunostaining was positive for β -catenin and negative for E-cadherin. This report presents a brief review of the current literature on primary ovarian solid pseudopapillary tumors, including a discussion of expected prognosis after surgical resection, as well as a discussion of the role of immunohistochemistry (IHC) in differentiating ovarian neoplasms in young premenopausal women.

1. Introduction

Primary ovarian solid pseudopapillary tumors (SPTs) are rare, with only 10 cases reported in the English literature at the time of this publication [1–8]. SPTs are more commonly found as primary pancreatic tumors. Pancreatic SPTs and ovarian SPTs have overlapping characteristic features on gross appearance and microscopic examination. They both tend to be indolent, and surgical resection generally leads to a very favorable prognosis. One of the key diagnostic features that distinguishes ovarian SPTs from other ovarian tumors is IHC: ovarian SPTs stain positive for nuclear and cytoplasmic β -catenin and exhibit a loss of membranous E-cadherin expression.

2. Clinical History

A 24-year-old African-American nulligravida female presented to a gynecologist with worsening pelvic pain and dysmenorrhea. She was otherwise healthy with regular monthly menses, no medical problems, no changes in weight, and no changes in bladder or bowel habits. Her family history was significant for a paternal grandmother with breast cancer at an unknown age. On physical exam, a palpable mass and tenderness were appreciated in the right adnexa. Pelvic ultrasound showed an enlarged right ovary measuring 5.24 cm \times 5.52 cm \times 3.22 cm with a solid heterogenous mass measuring 3.4 cm \times 3.3 cm \times 3.8 cm (Figure 1). This irregular solid tumor demonstrated blood flow (color score $<$ 4) with no




FIGURE 3: (a) Pseudopapillary growth pattern characteristic of solid pseudopapillary tumors (magnification $\times 100$, H&E). (b) Another view of pseudopapillary growth pattern characteristic of solid pseudopapillary tumors (magnification $\times 100$, H&E). (c) Tumor cells with characteristic eccentric nuclei and extracellular eosinophilic hyaline globules (magnification $\times 200$, H&E). (d) β -catenin immunohistochemical staining shows nuclear and cytoplasmic positive staining (magnification $\times 100$, β -catenin).

negative for inhibin (a marker for sex-cord stromal tumors), synaptophysin (a marker for neuroendocrine tumors), SOX10 (a marker for melanoma), and pancytokeratin (a marker for epithelial tumors). The specimen in our case had positive immunostaining for nuclear and cytoplasmic β -catenin (Figure 3(d)) and negative immunostaining for membranous E-cadherin, both of which are specifically diagnostic of SPTs.

A comparison of our case to other reported cases of ovarian SPTs revealed several similarities. Ovarian SPTs most frequently occur in young premenopausal women, with an overall age range of 17-57 years. Typical presenting symptoms include abdominal pain, bloating, swelling, and fullness; decreased appetite and weight loss have also been reported. On gross examination, the tumors range in size from 3 cm to 25.5 cm and are usually well-circumscribed masses with both cystic and solid components, although some ovarian SPTs are cystic only. In terms of tumor site, there does not appear to be a predominance of the left ovary versus the right ovary. As with primary pancreatic SPTs, the majority of primary ovarian SPTs have an indolent course, and prognosis is usually very favorable after surgical resection [9]. However, in one exceptional case, metastases of

the primary ovarian SPT were noted to the omentum, parametrium, and pelvic lymph nodes; after surgical management (i.e., right salpingo-oophorectomy, total omentectomy, pelvic lymph node dissection, and tumor debulking), the patient remained disease-free on a CT scan 18 months after surgery. In another exception case, the primary ovarian SPT involved the fallopian tube, omentum, cul-de-sac, and abdominal wall; the patient died within 8 months after initial diagnosis despite surgical cytoreduction and adjuvant chemotherapy (3 cycles of carboplatin and paclitaxel followed by 3 cycles of carboplatin and gemcitabine) [4].

Given the rarity of primary ovarian SPTs in the literature, optimal treatment and surveillance remain unclear. In our case, a thorough laparoscopic examination of the abdomen and pelvis revealed no evidence of ascites, carcinomatosis, or metastasis. A CT scan of the abdomen was recommended after surgery to complete evaluation for intraabdominal lesions, particularly in the pancreas. However, the patient conceived shortly after her surgery and declined a CT scan during her pregnancy. Regardless, she is expected to have an indolent course with good prognosis, given that her ovarian SPT histologically did not exhibit as much mitotic activity or necrosis compared to pancreatic SPTs.

Data Availability

N/A.

Consent

The patient has signed an informed consent form stating that she agrees to give the authors full permission to use her protected health information, with all personal identifiers removed, for the purposes of clinical research, discussion, presentation, and publication.

Conflicts of Interest

The authors have no relevant financial relationships or conflicts of interest to report.

Authors' Contributions

All authors contributed to the literature search. Michelle Nguyen and Melissa Hodeib drafted the manuscript. Michael Carter provided details for clinical history information as the primary physician caring for this patient. Zimin Zhao performed the pathologic evaluation and provided the figures. All authors critically reviewed, edited, and approved the final manuscript for publication.

References

- [1] V. Deshpande, E. Oliva, and R. H. Young, "Solid pseudopapillary neoplasm of the ovary: a report of 3 primary ovarian tumors resembling those of the pancreas," *The American Journal of Surgical Pathology*, vol. 34, no. 10, pp. 1514–1520, 2010.
- [2] W. Cheuk, I. Beavon, D. T. Y. Chui, and J. K. C. Chan, "Extrapancreatic solid pseudopapillary Neoplasm," *International Journal of Gynecological Pathology*, vol. 30, no. 6, pp. 539–543, 2011.
- [3] L. M. Stoll, R. Parvataneni, M. W. Johnson, D. Gui, O. Dorigo, and P. Sullivan, "Solid pseudopapillary neoplasm, pancreas type, presenting as a primary ovarian neoplasm," *Human Pathology*, vol. 43, no. 8, pp. 1339–1343, 2012.
- [4] S. Syriac, J. Kesterson, I. Izevbaye, K. L. de Mesy Bentley, S. Lele, and P. Mhawech-Fauceglia, "Clinically aggressive primary solid pseudopapillary tumor of the ovary in a 45-year-old woman," *Annals of Diagnostic Pathology*, vol. 16, no. 6, pp. 498–503, 2012.
- [5] A. Kominami, M. Fujino, H. Murakami, and M. Ito, " β -Catenin mutation in ovarian solid pseudopapillary neoplasm," *Pathology International*, vol. 64, no. 9, pp. 460–464, 2014.
- [6] S. He, X. Yang, P. Zhou, Y. Cheng, and Q. Sun, "Solid pseudopapillary tumor: an invasive case report of primary ovarian origin and review of the literature," *International Journal of Clinical and Experimental Pathology*, vol. 8, no. 7, pp. 8645–8649, 2015.
- [7] G. P. Gahlot, A. R. Mridha, M. Sable, M. C. Sharma, R. Pramanik, and L. Kumar, "Solid pseudopapillary neoplasm of the ovary with metastases to the omentum and regional lymph nodes," *Indian Journal of Pathology & Microbiology*, vol. 59, no. 3, pp. 348–350, 2016.
- [8] K. Singh, N. Patel, P. Patil, C. Paquette, C. A. Mathews, and W. D. Lawrence, "Primary ovarian solid pseudopapillary neoplasm with CTNNB1 c.98C>G (p.S33C) point mutation," *International Journal of Gynecological Pathology*, vol. 37, no. 2, pp. 110–116, 2018.
- [9] X. Guo, N. Li, K. Ren et al., "Extrapancreatic solid pseudopapillary tumors: a clinicopathological analysis of two cases," *Molecular and Clinical Oncology*, vol. 4, no. 5, pp. 845–850, 2016.
- [10] Q. Chen, W. Lu, and W. Lv, "Overlap of microcystic stromal tumor and primary solid pseudopapillary neoplasm of the ovary," *International Journal of Clinical and Experimental Pathology*, vol. 8, no. 9, pp. 11792–11797, 2015.